Published in Osteoporos Int on August 29, 2012
An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide. Osteoporos Int (2013) 0.90
Effects of sequential osteoporosis treatments on trabecular bone in adult rats with low bone mass. Osteoporos Int (2014) 0.82
Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects. AAPS PharmSciTech (2015) 0.81
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med (2003) 7.25
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc (2006) 5.32
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int (2000) 4.85
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med (2005) 4.03
Compliance with osteoporosis medications. Arch Intern Med (2005) 2.91
The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int (2004) 2.88
Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int (2006) 2.79
Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone (2005) 2.66
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med (2007) 2.64
Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int (2006) 2.53
Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum (2009) 2.16
Anabolic actions of parathyroid hormone on bone. Endocr Rev (1993) 2.13
Compliance with osteoporosis therapy is the weakest link. Lancet (2006) 1.84
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res (2008) 1.78
Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab (2010) 1.77
Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos Int (2006) 1.72
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med (2004) 1.51
Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab (2003) 1.19
Treatment of postmenopausal women with osteoporosis with PTH(1-84) for 36 months: treatment extension study. Curr Med Res Opin (2010) 0.78
Risk of new vertebral fracture in the year following a fracture. JAMA (2001) 6.17
Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab (2001) 6.12
A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med (1999) 4.91
Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. CMAJ (2000) 3.77
Genetic variability in adult bone density among inbred strains of mice. Bone (1996) 3.66
HIV disease and the endocrine system. N Engl J Med (1992) 3.48
Structural and evolutionary relationships among protein tyrosine phosphatase domains. Mol Cell Biol (2001) 3.37
Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int (2007) 3.12
Insulin-like growth factor-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab (1997) 3.00
Quantitative trait loci for femoral and lumbar vertebral bone mineral density in C57BL/6J and C3H/HeJ inbred strains of mice. J Bone Miner Res (2001) 2.94
Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab (1999) 2.79
Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab (2009) 2.69
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2000) 2.40
Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab (2000) 2.34
The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int (2001) 2.32
Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham Heart Study. J Clin Endocrinol Metab (1998) 2.14
Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab (2000) 2.14
Brain: gadolinium-enhanced fast fluid-attenuated inversion-recovery MR imaging. Radiology (1999) 2.07
Adipogenesis is inhibited by brief, daily exposure to high-frequency, extremely low-magnitude mechanical signals. Proc Natl Acad Sci U S A (2007) 2.04
Gender-specific changes in bone turnover and skeletal architecture in igfbp-2-null mice. Endocrinology (2008) 2.03
Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab (2000) 2.00
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int (1999) 1.98
Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology (2000) 1.93
Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab (1996) 1.92
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int (2009) 1.85
Dietary changes favorably affect bone remodeling in older adults. J Am Diet Assoc (1999) 1.84
Treatment failure in osteoporosis. Osteoporos Int (2012) 1.82
Osteoporosis and low bone mass in premenopausal and perimenopausal women. Endocr Pract (2001) 1.81
Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Clin Endocrinol Metab (1995) 1.79
Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int (2010) 1.74
Mechanism of tryptophanase induction in Escherichia coli. J Mol Biol (1967) 1.71
Neuromuscular disease in primary hyperparathyroidism. Ann Intern Med (1974) 1.69
Quantitative trait loci for bone density in C57BL/6J and CAST/EiJ inbred mice. Mamm Genome (1999) 1.68
Mutations of the GNAS1 gene, stromal cell dysfunction, and osteomalacic changes in non-McCune-Albright fibrous dysplasia of bone. J Bone Miner Res (2000) 1.65
Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology (1998) 1.64
Whole-body vibration slows the acquisition of fat in mature female rats. Int J Obes (Lond) (2008) 1.64
Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int (2009) 1.63
Primary hyperparathyroidism: clinical and biochemical features. Medicine (Baltimore) (1974) 1.63
Interleukin-6: a potential mediator of the massive osteolysis in patients with Gorham-Stout disease. J Clin Endocrinol Metab (1996) 1.59
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) (2000) 1.59
Marked improvement in bone mass after parathyroidectomy in osteitis fibrosa cystica. J Clin Endocrinol Metab (1998) 1.58
Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab (2000) 1.58
Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab (1998) 1.56
Prevalence of IgA-antiendomysial antibody in asymptomatic low bone mineral density. Am J Gastroenterol (2001) 1.54
Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab (2007) 1.53
On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab (1999) 1.53
Assessment of trabecular and cortical architecture and mechanical competence of bone by high-resolution peripheral computed tomography: comparison with transiliac bone biopsy. Osteoporos Int (2009) 1.52
The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab (1990) 1.51
'Senile' osteoporosis reconsidered. JAMA (1989) 1.51
The influence of hyperthyroidism and hypothyroidism on alpha- and beta-adrenergic receptor systems and adrenergic responsiveness. Endocr Rev (1983) 1.51
Thoracic, but not lumbar, epidural anesthesia improves cardiopulmonary function in ovine pulmonary embolism. Anesth Analg (2001) 1.50
Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab (1998) 1.49
The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2007) 1.48
The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2003) 1.47
Progressive atrophy of the frontal lobes in first-episode schizophrenia: interaction with clinical course and neuroleptic treatment. Acta Psychiatr Scand (1999) 1.46
Critical impact of patient knowledge and bone density testing on starting osteoporosis treatment after fragility fracture: secondary analyses from two controlled trials. Osteoporos Int (2014) 1.45
Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int (2000) 1.45
Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone (2007) 1.43
Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis. Am Fam Physician (2000) 1.43
New insights into osteoporosis: the bone-fat connection. J Intern Med (2012) 1.43
The hypothalamus-pituitary-adrenal axis in HIV disease. AIDS Read (2003) 1.42
Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab (2001) 1.42
Growth hormone deficiency and replacement in elderly hypopituitary adults. KIMS Study Group and the KIMS International Board. Pharmacia and Upjohn International Metabolic Database. Clin Endocrinol (Oxf) (2000) 1.41
Assessment by quantitative ultrasonometry of the effects of hormone replacement therapy on bone mass. Am J Obstet Gynecol (2000) 1.40
Hypergonadotropic hypogonadism in a patient with inv ins (2;4). Int J Androl (2007) 1.40
The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med (1999) 1.40
Primary hyperparathyroidism: still evolving? J Bone Miner Res (1997) 1.39
Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med (1990) 1.39
[Measuring bone density with ultrasound--ready for general practice?]. Zentralbl Gynakol (1998) 1.39
Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab (2007) 1.39
Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab (2003) 1.38
"Evidence-based" or "logic-based" medicine? Osteoporos Int (2010) 1.38
Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology (2006) 1.36
Genetic regulation of cortical and trabecular bone strength and microstructure in inbred strains of mice. J Bone Miner Res (2000) 1.35
25-Hydroxyvitamin D in Canadian adults: biological, environmental, and behavioral correlates. Osteoporos Int (2010) 1.34
Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med (1986) 1.34
Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism: patient description and effects on the SF-36 health survey. Surgery (2000) 1.33
Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int (2011) 1.33
Effect of beta-adrenergic catecholamines on sodium transport in turkey erythrocytes. J Biol Chem (1973) 1.31
Postnatal and pubertal skeletal changes contribute predominantly to the differences in peak bone density between C3H/HeJ and C57BL/6J mice. J Bone Miner Res (2001) 1.31
Parathyroid carcinoma: a review of 62 patients. Endocr Rev (1982) 1.30
Minor head injury: impact on general health after 1 year. A prospective follow-up study. Acta Neurol Scand (1992) 1.30
A study of complaints and their relation to vertebral destruction in patients with osteoporosis. Bone Miner (1990) 1.30
Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos Int (2014) 1.29
Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts. Osteoporos Int (2010) 1.27
Clinical review 63: Diabetes and pancreatic cancer: clues to the early diagnosis of pancreatic malignancy. J Clin Endocrinol Metab (1994) 1.25
Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int (2010) 1.25
Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos. Osteoporos Int (2010) 1.24
Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis. Osteoporos Int (2010) 1.24
Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis. J Bone Miner Res (1992) 1.23
Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med (1987) 1.23
Relation between vitamin D insufficiency, bone density, and bone metabolism in healthy postmenopausal women. J Bone Miner Res (2001) 1.23
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res (2002) 1.22